A Learning Programme for Professionals
WHO invites Member States, health facilities and other entities to participate in the global effort to collect anonymized clinical data relating to suspected or confirmed cases of monkeypox and contribute data to the WHO Global Clinical Platform.
WHO has developed a clinical characterization case ...report forms (CRF) to standardize data collection of clinical features of monkeypox among outpatient and hospitalized cases.
For onboarding to the WHO Global Clinical Platform for monkeypox, please contact: monkeypox_clinicaldataplatform@who.int
more
Just about everyone has experienced the joy that a healthy newborn child brings to parents, families and communities. But the arrival of a newborn who is small or sick often results in immediate worry and sadness. When the infant is at high risk of death or disability, these concerns can be a tremen...dous additional burden.
more
January 2019
Non Communicable Disease Control Programme Directorate General of Health Services Health Services Division, Ministry of Health & Family Welfare
A National Service Programme for All Children with Special Needs and their Families
In Myanmar, we estimate that at least 40% of children require ECI services for short to longer periods of time. At present, 35.1% of Myanmar children are moderately to severely stunted; all of these children are l...ikely to have one or more developmental delays. In addition, at least 5% to 12% of the nation’s children will be identified to have disabilities, chronic diseases or atypical behaviours.
Over time, approximately 70% of the children who will be served will improve in their development, attain expected levels of development for their age, and will consolidate their gains within one to two years. Other children, approximately 30%, will have lifelong disabilities or other conditions, and ECI services usually greatly improve their development and help them to achieve their full potential.
more
The Impact of the Zika Outbreak on Women and Girls in Northeastern Brazil
THELANCETID-D-16-00800 S1473-3099(16)30318-8
BMC Medicine201614:112 DOI: 10.1186/s12916-016-0660-0
Bulletin of the World Health Organization; http://dx.doi.org/10.2471/BLT.16.176677
Versão 2. Última atualização 10 Março 2016
O protocolo contém orientações sobre definição de casos suspeitos, como identificação de alterações do Sistema Nervoso Central (SNC) durante a gestação, critérios para confirmação ou descarte de casos, sistema de notificação e investig...ação laboratorial. Além disso, há orientações sobre como deve ser feita a investigação epidemiológica dos casos suspeitos e sobre o monitoramento e análise de dados.
more
This publication seeks to describe the best treatments and practices based on the scientific evidence available at the time of writing as evaluated by the authors and may change as a result of new research. Readers need to apply this knowledge to patients in accordance with the guidelines and laws o...f their country of practice. Some medications may not be available in some countries and readers should consult the specific drug information since not all the unwanted effects of medications are mentioned.
more